(NASDAQ: AUPH) Aurinia Pharmaceuticals's forecast annual revenue growth rate of 20.74% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Aurinia Pharmaceuticals's revenue in 2023 is $158,853,000.On average, 3 Wall Street analysts forecast AUPH's revenue for 2023 to be $24,903,091,719, with the lowest AUPH revenue forecast at $24,643,304,551, and the highest AUPH revenue forecast at $25,107,015,312. On average, 5 Wall Street analysts forecast AUPH's revenue for 2024 to be $31,397,483,720, with the lowest AUPH revenue forecast at $25,863,830,336, and the highest AUPH revenue forecast at $34,707,221,076.
In 2025, AUPH is forecast to generate $40,158,874,197 in revenue, with the lowest revenue forecast at $28,906,887,332 and the highest revenue forecast at $48,107,298,858.